openPR Logo
Press release

Von Hippel Lindau Disease Market Business Strategies, Regional Developments, Demand, and Forecast to 2031 | Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc.

11-13-2024 08:20 AM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research

Von Hippel Lindau Disease Market || 2024-2031

Von Hippel Lindau Disease Market || 2024-2031

The Von Hippel Lindau Disease Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/von-hippel-lindau-disease-market

What is the projected growth rate (CAGR) of the Global Von Hippel Lindau Disease market from 2024 to 2031, and what is the market value expected to change by 2031?

The global von Hippel-Lindau disease market reached US$ 293.47 million in 2023 and is expected to reach US$ 501.24 million by 2031 growing with a CAGR of 6.92% during the forecast period 2024-2031.

The Von Hippel-Lindau (VHL) Disease Market focuses on treatments for VHL, a rare genetic disorder that causes tumors and cysts to form in various organs, including the kidneys, eyes, and brain. The market is driven by advancements in targeted therapies, genetic research, and early detection methods. Increased awareness and growing demand for personalized treatment options are also contributing to the market's growth, as more effective management solutions for VHL are developed.

Key Developments:

In December 2023, Merck announced that the U.S. Food and Drug Administration (FDA) approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. This medication is intended for adult patients with advanced renal cell carcinoma (RCC) who have previously received treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, as well as a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

In August 2021, Merck acquired the rights to Belzutifan, another HIF-2α inhibitor, from Peloton Therapeutics in a $1.2 billion deal. This acquisition allowed Merck to expand its portfolio in the field of targeted cancer therapies.

List of the Key Players in the Von Hippel Lindau Disease Market:

Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Amgen Inc., Betta Pharmaceuticals Co., Ltd, Amneal Pharmaceuticals, Inc., Reliance Life Sciences, Lupin, Sandoz, Inc., and Biogen among others.

Research Process:

Both primary and secondary data sources have been used in the global Von Hippel Lindau Disease Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Von Hippel Lindau Disease Market:

By Tumor Site: Brain, Spinal Cord, Eyes, Inner Ear, Reproductive Tract, Kidney, Others.

By Treatment: Drug Type, Surgeries, Others.

By End-User: Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Others.

Regional Breakout:

The global Von Hippel Lindau Disease Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

✫ North America (U.S., Canada, Mexico)

✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

✫ South America (Colombia, Brazil, Argentina, Rest of South America)

✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=von-hippel-lindau-disease-market

This Report Unveils:

✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.

✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.

✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.

✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.

✔ Identify high-potential niche segments and regions poised for significant expansion.

✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.

✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Von Hippel Lindau Disease manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Von Hippel Lindau Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the Von Hippel Lindau Disease market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the Von Hippel Lindau Disease market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/von-hippel-lindau-disease-market

Frequently Asked Questions

☞ What is the expected growth rate of the global Von Hippel Lindau Disease market for the forecast period?

☞ What are the key driving factors that are responsible to shape the fate of the Von Hippel Lindau Disease market during the forecast period?

☞ What will be the overall size of the market during the analysis period?

☞ What are the prominent market trends which influence the development of the Von Hippel Lindau Disease market across various regions?

☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☞ What are the challenges and threats that are likely to act as a barrier to the growth of the Von Hippel Lindau Disease market?

☞ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Von Hippel Lindau Disease Market Business Strategies, Regional Developments, Demand, and Forecast to 2031 | Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc. here

News-ID: 3732330 • Views:

More Releases from DataM Intelligence 4Market Research

United States Peripheral Neuropathy Market Set for Transformative Growth with Rising Treatment Innovations 2025 | Top key players - GlaxoSmithKline, Abbott Laboratories, Cipla Laboratories.
United States Peripheral Neuropathy Market Set for Transformative Growth with Ri …
Market Size and Growth: The Peripheral Neuropathy Market size was valued US$ 1,539 million in 2021 and is estimated to reach US$ YY million by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031). The Peripheral Neuropathy Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants
United States Acute Coronary Syndrome Market Set for Robust Growth with Advancements in Treatment & Rising Cardiovascular Cases 2025 | Top key players - Merck, Novartis, Amgen Inc.
United States Acute Coronary Syndrome Market Set for Robust Growth with Advancem …
Market Size and Growth: The Global Acute Coronary Syndrome Market size reached US$ 9.94 billion in 2023 and is expected to reach US$ 14.70 billion by 2031, growing at a CAGR of 5.1% during the forecast period 2024-2031. The Acute Coronary Syndrome Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for
United States Atrial Fibrillation Market Surges with Breakthrough Therapies and Rising Patient Demand 2025 | Top key players - AdvaCare Pharma, Sanofi, Pfizer Inc.
United States Atrial Fibrillation Market Surges with Breakthrough Therapies and …
Market Size and Growth: The Global Atrial Fibrillation Market size reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033. The Atrial Fibrillation Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market
United States Personalized Cancer Vaccines Market Set for Breakthrough Growth with Innovative Therapies Revolutionizing Oncology Care 2025 | Major key players - BioNTech SE, Merck & Co., Inc., Moderna, Inc.
United States Personalized Cancer Vaccines Market Set for Breakthrough Growth wi …
Market Size and Growth: The Global Personalized Cancer Vaccines Market size reached US$ 11.33 Billion in 2024 from US$ 10.21 Billion in 2023 and is expected to reach US$ 30.12 Billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033. The Personalized Cancer Vaccines Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in

All 5 Releases


More Releases for Hippel

Von Hippel-Lindau (VHL) Disease Market to Reach USD 890 Million by 2034
Von Hippel-Lindau (VHL) disease is a rare, inherited genetic disorder caused by mutations in the VHL tumor suppressor gene. It predisposes individuals to the development of multiple benign and malignant tumors across various organs, including the kidneys, pancreas, adrenal glands, retina, and central nervous system. The most life-threatening complications include renal cell carcinoma (RCC), pheochromocytomas, and central nervous system hemangioblastomas. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71711 Although
Von Hippel-Lindau (VHL) Disease Market to Reach USD 7.8 Billion by 2034
Von Hippel-Lindau (VHL) disease is a rare inherited disorder caused by mutations in the VHL tumor suppressor gene, leading to the development of benign and malignant tumors in multiple organs, including the kidneys, pancreas, adrenal glands, and central nervous system. The prevalence of VHL disease is estimated at 1 in 36,000 live births worldwide, and its multisystem involvement poses significant treatment challenges. Download Full PDF Sample Copy of Market Report @
Von Hippel-Lindau Disease Market Future Business Opportunities 2025-2032 |
The Von Hippel-Lindau Disease Market is estimated to be valued at USD 325.3 million in 2025 and is expected to reach USD 557.5 million by 2032, growing at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2032. The Latest published market study on Von Hippel-Lindau Disease Market report provides an overview of the current market dynamics as well as what our survey respondents- all outsourcing decision-makers- predict the
Von Hippel-Lindau Disease Market Future Business Opportunities 2025-2032 | Merck …
The Von Hippel-Lindau Disease Market is estimated to be valued at USD 301.2 million in 2024 and is expected to reach USD 510.3 million by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031. According to the latest research from CoherentMI, the Von Hippel-Lindau Disease Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based
Von Hippel-Lindau Market Size to Exhibit Moderate Growth by 2034, Evaluates Delv …
DelveInsight's "Von Hippel-Lindau Disease (VHL) Disease Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Von Hippel-Lindau disease epidemiology, market, and clinical development understanding of top oncogenic drivers/biomarkers in Von Hippel-Lindau disease , Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Von Hippel-Lindau disease market trends in the United States, EU4 (Germany, Spain,
Von Hippel-Lindau Disease Treatment Market Size 2034 | Roche, Exelixis, Bayer, N …
DelveInsight's "Von Hippel-Lindau Disease (VHL) Disease - Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Von Hippel-Lindau disease epidemiology, market, and clinical development understanding of top oncogenic drivers/biomarkers in Von Hippel-Lindau disease , Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Von Hippel-Lindau disease market trends in the United States, EU4 (Germany,